CStone Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

CStone Pharmaceuticals şirketinin toplam hissedar öz sermayesi CN¥467.7M ve toplam borcu CN¥306.4M olup, bu da borç-öz sermaye oranını 65.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥1.5B ve CN¥1.1B dir.

Anahtar bilgiler

65.5%

Borç/özkaynak oranı

CN¥306.42m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥857.65m
Eşitlik	CN¥467.66m
Toplam yükümlülükler	CN¥1.06b
Toplam varlıklar	CN¥1.53b

Son finansal sağlık güncellemeleri

Recent updates

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

Oct 04

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

May 12

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Mar 04

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Jan 18

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Oct 04

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Oct 03

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Oct 20

Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?

Dec 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2616 'nin kısa vadeli varlıkları ( CN¥1.2B ) kısa vadeli yükümlülüklerini ( CN¥713.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2616 şirketinin kısa vadeli varlıkları ( CN¥1.2B ) uzun vadeli yükümlülüklerini ( CN¥351.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2616 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 2616 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 65.5% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 2616 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 2616 serbest nakit akışı her yıl % { 8.1 1.7 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

CStone Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?

Recent updates

Non-Executive Director recently bought HK$1.9m worth of stock

CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

Key Executive recently bought HK$1.5m worth of stock

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

Consensus revenue estimates decrease by 38%, EPS upgraded

CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024

CStone Pharmaceuticals Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer

CStone Pharmaceuticals Announces Change of Joint Company Secretary

CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024

CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA

Forecast to breakeven in 2026

CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Consensus EPS estimates fall by 38%

New minor risk - Share price stability

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma

CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma

CEO, Senior VP & Chief Medical Officer recently bought HK$385k worth of stock

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application

CEO, Senior VP & Chief Medical Officer recently bought HK$1.1m worth of stock

CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023

CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer

CEO, Senior VP & Chief Medical Officer recently bought HK$676k worth of stock

CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023

CEO, Senior VP & Chief Medical Officer recently bought HK$285k worth of stock

CEO, Senior VP & Chief Medical Officer recently bought HK$457k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2024

No longer forecast to breakeven

CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million.

CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022

Cstone Pharmaceuticals Announces Management Changes

CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China

CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints

CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist

Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022

CEO, Senior VP & Chief Medical Officer recently bought HK$2.2m worth of stock

Less than half of directors are independent

Forecast to breakeven in 2024

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals

CEO, Senior VP & Chief Medical Officer recently bought HK$668k worth of stock

CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab

CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022

CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022

CStone Pharmaceuticals Announces Executive Changes

Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

Forecast to breakeven in 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022

CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022

CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022

CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022

Less than half of directors are independent

CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC

CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo

CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022

CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC

CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibsovo® (Ivosidenib Tablets) as A New Precision Therapy for Patients with Acute Myeloid Leukemia